Press Releases
World’s Leading Life Science Companies Now Enrolling COMMUNITY, A Global, Platform Trial For Hospitalized Patients With COVID-19
Three members of the COVID R&D Alliance - Amgen Inc., Takeda Pharmaceutical Co. Ltd. and UCB announced the first patient enrolled in the COMMUNITY...
Clinical Trials
Algernon completes patient enrollment in phase 2b/3 study of Ifenprodil to treat COVID-19
Algernon Pharmaceuticals, a clinical stage pharmaceutical development company, announced that the final patient has been enrolled in its multinational phase 2b/3 human study of...
Drug Research
Sterling announces strategic investment in ADC Biotechnology
Global contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions (Sterling), has announced a new strategic partnership with ADC Biotechnology (ADC Bio), a UK...
News
FDA Grants Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to COVID-19
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States FDA has granted Fast Track designation for remestemcel-L...
News
Janssen Inc Announces the Initiation of a Rolling Submission for its Single-dose Janssen COVID-19 Vaccine Candidate with Health Canada
Janssen Inc. the pharmaceutical companies of Johnson & Johnson, has initiated a rolling submission with Health Canada for its investigational single-dose vaccine candidate for...
News
EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2
EMA has received an application for conditional marketing authorisation (CMA) for BNT162b2, a COVID?19 mRNA vaccine developed by BioNTech and Pfizer. The assessment of...
Press Releases
Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies
Eisai Co., Ltd. and Wren Therapeutics Ltd. announced that the companies have entered into an exclusive research collaboration agreement aiming to advance the discovery...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read